Well, if FDA agreed, it shouldn't be difficult to hit. Both Xarelto ph3 in same indication with varying enoxaparin treatment durations I referenced in previous posting had p<0.001, and both trials are much smaller than betrixaban ph3, actually the two combined are smaller than single betrixaban trial.
Market Data 
Markets 
AI
